MEDICAMEN BIOTECH LTD.-$

Medicamen Biotech Ltd has filed its Annual Report for the financial year 2025-26, coinciding with the notice for its 33rd Annual General Meeting (AGM). The AGM will be held on September 26, 2026, via Video Conferencing/Other Audio Visual Means. The report includes the Business Responsibility and Sustainability Report and details the company's strategic progress, including strengthening its oncology division, expanding market presence, and accelerating growth in domestic and international markets. The company has also facilitated remote e-voting for shareholders from September 23 to September 25, 2026.

Medicamen Biotech Ltd has submitted its Integrated Annual Report for the Financial Year 2025-26, as per SEBI regulations. The report includes the notice for the 16th Annual General Meeting (AGM) scheduled for September 29, 2026. The Annual Report and AGM notice are also available on the company's website, www.eightyjewels.in. The filing details the company's performance, vision, mission, and corporate structure, including its board of directors and key managerial personnel. The report covers financial statements like the Balance Sheet, Profit and Loss Statement, and Cash Flow Statement, along with management discussions and auditor's reports.

Medicamen Biotech Ltd has announced its 33rd Annual General Meeting (AGM) will be held on Saturday, September 26, 2026, commencing at 12:00 Noon IST. The meeting will be conducted entirely through Video Conferencing/Other Audio Visual Means (VC/OAVM) in compliance with Ministry of Corporate Affairs (MCA) circulars. The Notice of the AGM and the Integrated Annual Report for FY 2025-26, including the Business Responsibility and Sustainability Report, are being sent electronically to shareholders. Shareholders have the facility to cast their vote electronically prior to and during the AGM. The remote e-voting period will be from September 23 to September 25, 2026. The cut-off date for determining voting eligibility is September 19, 2026.

Medicamen Biotech Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, in compliance with SEBI regulations. The report details the company's corporate identity, operational activities, and financial performance. Key financial figures for FY 2025-26 include a paid-up capital of ₹13,56,28,150, total turnover of ₹178,84,58,167, and profit after taxes of ₹9,40,86,731. The company reported spending ₹25,20,000 on CSR activities, falling short of the statutory requirement by ₹6,13,024. Medicamen Biotech also disclosed its two subsidiaries, OPAL Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited, and confirmed that its Chairman, Rahul Bishnoi, is responsible for BR policy implementation.

Medicamen Biotech Ltd has announced Saturday, September 19, 2026, as the record date for determining shareholder entitlement to a potential final dividend for the Financial Year 2025-26. The dividend, if declared at the upcoming 33rd Annual General Meeting (AGM), will be paid to members registered on the record date. The company's Register of Members and Share Transfer Books will be closed from September 20, 2026, to September 26, 2026, inclusive, for the AGM and dividend payment purposes. This announcement complies with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Medicamen Biotech Limited has announced that the Board of Directors has fixed September 19, 2026, as the record date for the declaration of a final dividend for the Financial Year 2025-26. The dividend, proposed at 10% or Re. 1/- per equity share, is subject to shareholder approval at the upcoming 33rd Annual General Meeting. The AGM is scheduled for September 26, 2026, to be held via Video Conferencing. The company also approved the draft Annual Report and Cost Audit Report for FY 2025-26 and noted recent communications from stock exchanges regarding compliance matters.

Medicamen Biotech Limited announced that its Board of Directors has approved the closure of its Register of Members and Share Transfer Books from September 19 to September 25, 2026. This closure is in connection with the proposed payment of a final dividend of 10%, or Re. 1/- per equity share, subject to shareholder approval at the upcoming 33rd Annual General Meeting (AGM). The AGM is scheduled for September 26, 2026, at 12:00 PM via Video Conferencing. The company also approved the draft Annual Report and Cost Audit Report for FY 2025-26 and took note of communications from stock exchanges regarding past non-compliance fines.

Medicamen Biotech's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue rose 11.3% YoY to ₹47.90 Cr from ₹43.04 Cr, with consolidated PAT up 15.3% YoY to ₹1.85 Cr from ₹1.60 Cr and EPS at ₹1.36 versus ₹1.18. Sequentially both lines fell sharply — revenue down 21.0% and PAT down 58.5% — off a stronger ₹60.65 Cr / ₹4.45 Cr March quarter. Management gives no formal guidance or outlook on record for this print to be checked against, and no analyst coverage or consensus estimates were found for the stock, so there is no street benchmark either; no management press release was available to cross-check against the reported numbers. Operating margin compressed to 9.03% from 10.72% a year ago, even though it was roughly flat sequentially (8.97% in Q4 FY26). The squeeze traces to other expenses, which rose 72.3% YoY to ₹13.14 Cr (from ₹7.63 Cr) on the consolidated base — outpacing the 11.3% revenue growth — while cost of material consumed actually improved as a share of revenue, falling to 47.2% from 57.1% a year earlier. Net margin held roughly steady at 3.79% versus 3.68% YoY (down sharply from 7.13% in Q4 FY26), as the lower material-cost ratio partly offset the other-expense drag. Standalone PAT of ₹2.53 Cr grew a much faster 54.4% YoY (from ₹1.64 Cr) — the gap versus consolidated growth of 15.3% is explained by a combined ₹0.69 Cr net loss at subsidiaries Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited on ₹4.04 Cr of subsidiary revenue this quarter, per the auditors' review report; the group (consolidated) figure is the weaker of the two bases. No exceptional items appear in either period, and both statements carry unmodified limited-review opinions. Separately, the board this quarter noted BSE and NSE fines of ₹1.11 lakh each for a Nomination & Remuneration Committee composition lapse (Regulation 19(1)/19(2)), already remitted on June 2, 2026 — a governance footnote with no bearing on the P&L.

Medicamen Biotech Ltd has announced a Board of Directors meeting scheduled for August 14, 2026. The primary agenda is to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. Additionally, the board will review the Draft Annual Report and Draft Cost Audit Report for the financial year 2025-26. The trading window for designated persons will remain closed from July 1, 2026, until 48 hours after the financial results are declared.

Medicamen Biotech Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. The window will be shut from July 01, 2026, and will reopen 48 hours after the declaration of the un-audited financial results for the quarter ended June 30, 2026. This measure is in compliance with the company's code of conduct for regulating trading by insiders. All concerned individuals have been advised against trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.